๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Indicators Affecting PVT Recanalization

Recruitingn/aAges 18 Years - 80 YearsAllShanghai Zhongshan Hospital
NCT07473375 on ClinicalTrials.gov โ†—
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

This is a retrospective-prospective study conducted at Zhongshan Hospital, Fudan University, to explore portal vein thrombosis (PVT) in patients with cirrhosis and gastroesophageal varices (GEV). It aimed to provide insights into the diagnosis, follow-up, and factors influencing PVT recanalization, to help patients, families, and healthcare providers understand the disease and related clinical management.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * diagnosed as cirrhosis and confirmed gastroesophageal varices by endoscopy; * all patients were diagnosed as PVT by CTA at admission. Exclusion Criteria: * patients with hepatocellular carcinoma; * patients with extrahepatic malignancies; * history of liver transplantation or TIPS; * lack of information regarding anticoagulation therapy๏ผ› * those with cavernous transformation of the portal vein(CTPV) .
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
โ€”
Shanghai, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy